Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Supplement use was also markedly higher in IBD patients, with vitamin D and iron supplementation being significantly more common in both UC and CD groups than in HC (p < 0.01) (Table 1).
Source: Cohort characteristics. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Cohort study.
Cohort study
Examines exposures and outcomes over time within a defined group.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
In this cohort study, three groups of adult participants were enrolled (aged ≥ 18 years), UC (n = 31), CD (n = 39), and healthy individuals (n = 49) as a control group.
Source: Methods.
In this cohort study, three groups of adult participants were enrolled (aged ≥ 18 years), UC (n = 31), CD (n = 39), and healthy individuals (n = 49) as a control group.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Disrupted terminal bilirubin catabolism links Lachnospiraceae depletion to inflammatory bowel disease
Cohort study · Frontiers in Microbiology · 2026
Original publication title
Disrupted terminal bilirubin catabolism links Lachnospiraceae depletion to inflammatory bowel disease
Copyright © 2026 Sabti, Lialin-Tzadikov, Ivanova, Dori-Bachash, Uzi-Gavrilov, Tik, Mashiach, Zorea, Mizrahi, Segal, Moyal-Attias, Elinav and Meijler.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
The gut microbiome mediates the reductive catabolism of bilirubin into urobilinoids, yet the bacteria and enzymes responsible for the later steps of this pathway remain largely unknown.
Source: BackgroundAbstract: What methods does the paper describe?
Here, we combine untargeted UPLC/HRMS metabolomics with shotgun metagenomic sequencing of fecal samples from 119 participants, including patients with Crohn’s disease, ulcerative colitis, and healthy controls, to map disruptions in the bilirubin catabolic pathway in inflammatory bowel disease (IBD).
Source: MethodsAbstract: Discussion
These findings implicate Lachnospiraceae as key mediators of the yet unknown enzymatic conversion of I-urobilinogen to stercobilinogen, extending the family’s known metabolic repertoire beyond short-chain fatty acid production. Given that bilirubin and its reduced metabolite stercobilinogen possess antioxidant properties, their depletion may contribute to the oxidative burden in the IBD gut. Conversely, the concurrent elevation of D-urobilin, which lacks these protective properties and has been linked to metabolic dysfunction in other contexts, may further exacerbate inflammation. Our results identify fecal bilirubin metabolites as candidate biomarkers of microbial dysbiosis in IBD and nominate specific Lachnospiraceae taxa for functional characterization of the missing stercobilinogen reductase.
Source: DiscussionAbstract: Results
We show that stercobilinogen and stercobilin, the terminal metabolites of this pathway, are depleted (p < 0.01) in IBD patients irrespective of disease subtype, while upstream intermediates, D-urobilinogen, remain unchanged. This metabolic bottleneck coincides with a marked reduction in members of the Lachnospiraceae family, specifically Blautia sp. SG-772 and three uncharacterized species, which show strong positive correlations with stercobilinogen and stercobilin levels.
Source: ResultsAuthors’ abstract
Background
The gut microbiome mediates the reductive catabolism of bilirubin into urobilinoids, yet the bacteria and enzymes responsible for the later steps of this pathway remain largely unknown.
Methods
Here, we combine untargeted UPLC/HRMS metabolomics with shotgun metagenomic sequencing of fecal samples from 119 participants, including patients with Crohn’s disease, ulcerative colitis, and healthy controls, to map disruptions in the bilirubin catabolic pathway in inflammatory bowel disease (IBD).
Results
We show that stercobilinogen and stercobilin, the terminal metabolites of this pathway, are depleted (p < 0.01) in IBD patients irrespective of disease subtype, while upstream intermediates, D-urobilinogen, remain unchanged. This metabolic bottleneck coincides with a marked reduction in members of the Lachnospiraceae family, specifically Blautia sp. SG-772 and three uncharacterized species, which show strong positive correlations with stercobilinogen and stercobilin levels.
Discussion
These findings implicate Lachnospiraceae as key mediators of the yet unknown enzymatic conversion of I-urobilinogen to stercobilinogen, extending the family’s known metabolic repertoire beyond short-chain fatty acid production. Given that bilirubin and its reduced metabolite stercobilinogen possess antioxidant properties, their depletion may contribute to the oxidative burden in the IBD gut. Conversely, the concurrent elevation of D-urobilin, which lacks these protective properties and has been linked to metabolic dysfunction in other contexts, may further exacerbate inflammation. Our results identify fecal bilirubin metabolites as candidate biomarkers of microbial dysbiosis in IBD and nominate specific Lachnospiraceae taxa for functional characterization of the missing stercobilinogen reductase.
Publication and source details
Original title: Disrupted terminal bilirubin catabolism links Lachnospiraceae depletion to inflammatory bowel disease
Omer Sabti; Ksenia Lialin-Tzadikov; Valeria Ivanova; Mally Dori-Bachash; Shaked Uzi-Gavrilov; Zohar Tik; Roi Mashiach; Alvah Zorea; Itzhak Mizrahi; Arik Segal; Keren Moyal-Attias; Eran Elinav; Michael M. Meijler
Frontiers in Microbiology · 2026
* Correspondence: Michael M. Meijler, meijler@bgu.ac.ilORCID: Alvah Zorea, orcid.org/0000-0001-6543-2259
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-10T21:54:14.165690+00:00
DOI: 10.3389/fmicb.2026.1871609 · PMC13526984